Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Sanofi-Aventis was formed on 20th August 2004 following the merger of Sanofi-Synthélabo and Aventis. Further to the success of Sanofi-Synthelabo's offer for Aventis, and as announced on 12th August, the settlement of the offers occurred on 20th August. Hence, Sanofi-Synthelabo controls Aventis with 95.47 per cent of the share capital.